Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor, PF-03463275, in healthy and schizophrenia subjects

Glycine transporter-1 (GlyT1) inhibitors may ameliorate cognitive impairments associated with schizophrenia (CIAS). The dose-related occupancy and target engagement of the GlyT1 inhibitor, PF-03463275 were studied to inform optimal dose selection for a clinical trial for CIAS.

Source: Biological Psychiatry - January 19, 2018 Category: Psychiatry Authors: Deepak Cyril D ’Souza, Richard E. Carson, Naomi Driesen, Jason Johannesen, Mohini Ranganathan, John H. Krystal, Yale GlyT1 Study Tags: Priority Communication Source Type: research